

**Long-Term Pioglitazone Therapy is Safe and Effective for Patients With Prediabetes or Type 2 Diabetes Mellitus (T2DM) and Non-alcoholic fatty liver disease.**

Cusi K, et al. Ann Intern Med. 2016 Jun 21. [*Epub ahead of print*]

- Efficacy and safety of long-term pioglitazone treatment in patients with non-alcoholic fatty liver disease and prediabetes/T2DM was assessed in a placebo-controlled trial (101 patients).
- Pioglitazone treatment significantly resolved hepatitis, reduced hepatic triglyceride content, and improved insulin sensitivity. All improvements persisted over 36 months of therapy.
- Overall rate of adverse events did not differ from placebo group.

**Long-term pioglitazone treatment is safe and effective in patients with prediabetes or T2DM and non-alcoholic fatty liver disease.**